- Home
- TKO vs INSM Comparison
TKO vs INSM Comparison
Compare TKO & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TKO
- INSM
- Stock Information
- Founded
- TKO 1980
- INSM 1988
- Country
- TKO United States
- INSM United States
- Employees
- TKO N/A
- INSM N/A
- Industry
- TKO
- INSM Biotechnology: Pharmaceutical Preparations
- Sector
- TKO
- INSM Health Care
- Exchange
- TKO Nasdaq
- INSM Nasdaq
- Market Cap
- TKO 13.1B
- INSM 12.6B
- IPO Year
- TKO N/A
- INSM 2000
- Fundamental
- Price
- TKO $159.84
- INSM $65.08
- Analyst Decision
- TKO Strong Buy
- INSM Strong Buy
- Analyst Count
- TKO 15
- INSM 16
- Target Price
- TKO $157.79
- INSM $95.36
- AVG Volume (30 Days)
- TKO 1.1M
- INSM 2.5M
- Earning Date
- TKO 05-08-2025
- INSM 05-08-2025
- Dividend Yield
- TKO 0.95%
- INSM N/A
- EPS Growth
- TKO N/A
- INSM N/A
- EPS
- TKO 1.18
- INSM N/A
- Revenue
- TKO $2,850,741,000.00
- INSM $381,030,000.00
- Revenue This Year
- TKO $57.90
- INSM $30.36
- Revenue Next Year
- TKO $21.48
- INSM $115.55
- P/E Ratio
- TKO $136.22
- INSM N/A
- Revenue Growth
- TKO 42.68
- INSM 20.77
- 52 Week Low
- TKO $97.37
- INSM $21.92
- 52 Week High
- TKO $179.09
- INSM $84.91
- Technical
- Relative Strength Index (RSI)
- TKO 52.78
- INSM 35.80
- Support Level
- TKO $161.88
- INSM $63.81
- Resistance Level
- TKO $150.86
- INSM $73.39
- Average True Range (ATR)
- TKO 4.71
- INSM 2.53
- MACD
- TKO 0.78
- INSM -0.38
- Stochastic Oscillator
- TKO 55.70
- INSM 13.26
About TKO TKO Group Holdings Inc.
TKO Group Holdings Inc is a premium sports and entertainment company that comprises UFC, the world's mixed martial arts organization, and WWE, an integrated media organization and the recognized leader in sports entertainment.
About INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.